Good Morning Reader,
Pull up (NYSE: CLDI) now. Read below...
Calidi Biotherapeutics Inc. is making waves in the market, climbing steadily and capturing the attention of market enthusiasts! With a limited float of just over 5 million shares, this stock is showing a highly bullish trend on the daily chart. As a leader in groundbreaking oncology research, Calidi is dedicated to empowering the immune system to fight cancer like never before. Don’t miss your chance to be part of this biotech revolution—this could be your next big win!
--
Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company pioneering innovative approaches to cancer treatment. With proprietary technology designed to enhance the immune system's ability to fight cancer, Calidi leverages novel cell-based platforms that utilize allogeneic stem cells to deliver powerful oncolytic viruses. These platforms are tailored for various oncology indications, including high-grade gliomas and solid tumors.
Calidi’s advanced off-the-shelf, universal cell-based delivery systems are designed to protect, amplify, and optimize the therapeutic impact of oncolytic viruses. This approach not only enhances treatment efficacy but also prioritizes patient safety. Additionally, the company’s preclinical enveloped virotherapies aim to target disseminated solid tumors, offering a dual strategy with the potential to treat or prevent metastatic disease.
Headquartered in San Diego, California, Calidi has been at the forefront of research since its founding in 2014. The company has secured patents in the United States and key international markets, covering its proprietary SuperNova technology and its integration with modern immunotherapies like checkpoint inhibitors. Calidi’s acquisition of a wholly-owned subsidiary in Bernried, Germany, in 2016 further bolstered its research and development capabilities.
In 2021, Calidi exclusively licensed the NeuroNova technology from Northwestern University and the City of Hope. This cutting-edge platform, developed over 15 years, has demonstrated strong efficacy in published clinical trials and represents a significant leap forward in cancer treatment.
Driven by rigorous research and a commitment to innovation, Calidi Biotherapeutics is unlocking the potential of immunotherapies to redefine cancer care and address therapy-resistant diseases.
Most Notable Catalysts for CLDI:
Key Data Presentation at ASCO 2025
● Calidi plans to submit an abstract for the ASCO Annual Meeting in June 2025.
● The abstract will highlight progress in selecting a lead clinical candidate for RTNova.
● This initiative complements ongoing clinical and preclinical efforts with SNV (SuperNova) and NNV (NeuroNova) virotherapies, demonstrating Calidi's innovative approach to revolutionizing cancer treatment.
Financial Position and Fundraising Updates
● Calidi’s cash balance as of December 31, 2024, was approximately $9.6 million.
● Recent fundraising efforts, including proceeds from its At-The-Market Offering Agreement (ATM), strengthened its financial position.
● As a result, Calidi terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors on January 23, 2025.
Statement from Leadership
● Allan Camaisa, CEO and Chairman, emphasized the significance of terminating the SEPA as a milestone in the company’s financing strategy.
● This move reflects Calidi’s focus on clinical and operational goals while enhancing shareholder value.
● The termination removes a potential overhang on the stock, aligning with the company’s commitment to financial stability and leadership in targeted systemic and localized antitumor virotherapies.
Progress in Virotherapy Development
● Calidi’s systemic virotherapy platform (RTNova enveloped virotherapies) has been accepted for presentation at the AACR Annual Meeting in April 2025.
● The FDA granted IND clearance for a Phase 1b/2 trial of CLD-101 for high-grade gliomas, led by Northwestern University.
● Patient enrollment for the trial is scheduled to begin in Q1 2025.
Ongoing Innovation
● Calidi continues to advance its virotherapy platforms, including both systemic and localized antitumor virotherapies.
● These milestones reflect the company’s dedication to pioneering new approaches to cancer treatment and improving patient outcomes.
